Plaintiffs Ask Calif. Court to Designate Onglyza Action ‘Complex’ For Discovery Purposes

SAN FRANCISCO — A group of plaintiffs accusing AstraZeneca of failing to adequately warn doctors and patients of the cardiac risks associated with its diabetes drug Onglyza have asked a California court to designate their case as “complex” for purposes of discovery.

In a June 1 application filed in the San Francisco County Superior Court, the 10 plaintiffs assert that their case meets the California Civil Rule of Court 3.400’s criteria for such designation because “adjudication may involve a number of pretrial motions and substantial documentary evidence.”

“The complex science issues, requirement for multiple experts, current and future Food and …